Journal of drug targeting

Delivering risperidone to the brain using nose-based solid fat nanoparticles

Updated

Abstract

The brain/blood ratio one hour post-administration of intranasal risperidone-loaded solid lipid nanoparticles (RSLNs) was 1.36 ± 0.06, significantly higher than the ratio for risperidone solution (0.17 ± 0.05).

  • RSLNs demonstrated higher hindlimb retraction time values compared to the risperidone solution, suggesting improved brain targeting.
  • The pharmacokinetics study in mice indicated nearly 10-fold and 5-fold increases in brain/blood ratios for intranasal RSLNs compared to intravenous risperidone solution and intravenous RSLNs, respectively.
  • Gamma scintigraphy imaging confirmed that RSLNs localized in the brain following both intravenous and intranasal administration.
  • These results suggest a potential direct nose-to-brain delivery route for nanoparticles administered through the nasal cavity.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free